newsfilter
← Earnings
Earnings Releases·

Ensysce Biosciences — Third Quarter 2026 Earnings Summary

  • Net loss attributable to common stockholders widened to $82.3 million in Q3 2026 from $3.7 million in the prior year period, driven primarily by a $79.9 million non-cash charge for acquired in-process research and development (IPR&D) related to CY200.
  • Cash and cash equivalents increased significantly to $29.7 million as of September 30, 2026, from $4.3 million at year-end 2025, supported by $21.1 million in net proceeds from financing activities, including a $19.6 million Series C private placement.
  • Strategic progress includes the completed acquisition of Cy Biopharma, Inc., adding CY200 as the lead pipeline asset, while the Phase 2a protocol for CY200 (CYBIO 001) was submitted to the MHRA in September 2026, with additional information requested on November 6, 2026.
  • The company expects continued losses for the foreseeable future as it advances product candidates, with recent financing proceeds designated primarily to advance CY200 through Phase 2a and prepare for registrational development.
Company
ENSYSCE BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology